Blis Technologies has emerged from a challenging year with a stronger financial position and a renewed sense of direction. The Dunedin-based probiotics innovator reported a net after-tax profit of $800,000 for the year ending March 31, an increase from $600,000 the previous year. Revenue also rose 10% to $12.6 million, while EBITDA improved by 26% to $1 million, signaling resilience and adaptability in a complex business environment.
Leadership credited much of the success to steady growth in finished product sales and positive developments in the company’s global business-to-business partnerships. While royalty income rose, some softness in European ingredient sales was noted. Nonetheless, strong performance in other international markets helped balance the overall picture.
A key challenge during the year stemmed from unexpected patent filings by Blis’s largest European customer. These filings, which became public in September, allegedly included confidential information shared under earlier agreements. Since then, Blis has been actively negotiating a resolution, with both parties aiming to finalize terms that would restore focus to expanding sales and deepening collaboration.
The US market continues to be a critical frontier, with Blis selling both bulk probiotic ingredients and finished products. Despite a 10% tariff on retail sales via Amazon and its online store, demand remains robust. Price adjustments implemented in April were designed to offset these tariff impacts without undermining growth.
Looking ahead to FY26, Blis Technologies enters with “cautious optimism.” As global demand for scientifically validated probiotics strengthens, the company remains committed to innovation, strategic partnerships, and sustainable growth.